Aduro Appoints Gregory W. Schafer as Chief Operating Officer
BERKELEY, Calif. -- July 23, 2013
Aduro BioTech, Inc. announces today the appointment of Gregory W. Schafer as
chief operating officer (COO). As COO, Mr. Schafer will lead the company’s
corporate strategy and operations.
“We are delighted to bring Greg into Aduro at this exciting time as we move
into later-stage clinical trials with our lead program for pancreatic cancer,”
said Stephen Isaacs, chairman and chief executive officer of Aduro. “We look
forward to leveraging Greg’s extensive experience in the industry,
particularly as it relates to planning and supporting the growing and more
complex operations of a biotechnology company progressing towards
Mr. Schafer brings more than 23 years of broad operational, financial and
strategic leadership expertise to Aduro and has raised over $650 million in
public and private transactions to fund biotechnology product development and
commercialization activities. Most recently, he served as chief financial
officer of Jennerex, Inc. for 3 years, where he was responsible for finance,
accounting, planning, investor relations and treasury functions. Prior to
Jennerex, he served as chief financial officer of Onyx Pharmaceuticals, Inc.,
where he was responsible for finance, accounting, risk management and
strategic and operational planning. Before joining Onyx, he served as chief
financial officer and vice president of finance for Cerus Corporation, where
he worked together with then-chief executive officer Stephen Isaacs to
transition the company from early-stage development to product approval. Prior
to Cerus, Mr. Schafer worked as a management consultant for Deloitte & Touche,
LLP and as an engineer specializing in biologics manufacturing. Mr. Schafer
also serves on the board of directors for Nile Therapeutics, a public
biotechnology company. He received his MBA from the Anderson Graduate School
of Management at the University of California, Los Angeles and a BSE in
mechanical engineering from the University of Pennsylvania.
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company located in
Berkeley, California. Aduro has completed enrollment in a randomized,
controlled Phase 2 clinical trial in patients with metastatic pancreatic
cancer and is conducting a Phase 1B trial in patients with malignant pleural
mesothelioma. In addition, the company’s preclinical pipeline includes
programs in glioblastoma, prostate cancer, melanoma, malaria, HBV and
Aduro BioTech, Inc.
Steven Bodovitz, Ph.D.
Press spacebar to pause and continue. Press esc to stop.